Mallinckrodt plc, a global specialty pharmaceutical company, announced that Japan's National Health Insurance (NHI) system has approved reimbursement for the Cellex extracorporeal photopheresis (ECP) system for the treatment of steroid-resistant or -intolerant chronic graft versus host disease (cGvHD).
